DUBLIN,
June 21, 2017
/PRNewswire/ -- Perrigo Company plc
(NYSE; TASE: PRGO) today announced it has
launched its generic equivalents to Hill Laboratories Inc.'s
Derma-Smoothe/FS® Scalp Oil (fluocinolone
acetonide scalp oil, 0.01%) and Derma-Smoothe/FS® Body
Oil (fluocinolone acetonide topical oil, 0.01%).
Derma-Smoothe/FS® Scalp Oil (fluocinolone
acetonide scalp oil, 0.01%) and Derma-Smoothe/FS® Body
Oil (fluocinolone acetonide topical oil, 0.01%) are indicated for
the topical treatment of atopic dermatitis in adult patients and
the topical treatment of moderate to severe atopic dermatitis in
pediatric patients 3 months and older for up to four weeks. These
products had combined annual market sales for the twelve months
ending April 2017 of approximately
$64 million.
Perrigo CEO John T.
Hendrickson stated, "This launch is another example of
Perrigo's ability to develop and bring to market important extended
topical treatments. As always, Perrigo is committed to making
quality healthcare more affordable for our customers, consumers and
families around the world."
About Perrigo
Perrigo Company plc, a leading global healthcare company,
delivers value to its customers and consumers by
providing Quality Affordable Healthcare
Products®. Founded in 1887 as a packager of home
remedies, Perrigo has built a unique business model that is best
described as the convergence of a fast-moving consumer goods
company, a high-quality pharmaceutical manufacturing organization
and a world-class supply chain network. Perrigo is the world's
largest manufacturer of over-the-counter ("OTC") healthcare
products and supplier of infant formulas for the store brand
market. The Company also is a leading provider of branded OTC
products throughout Europe and
the U.S., as well as a leading producer of "extended topical"
prescription drugs. Perrigo, headquartered
in Ireland, sells its products
primarily in North America and Europe, as well
as in other markets,
including Australia, Israel and China.
Visit Perrigo online at
(http://www.perrigo.com).
Forward-Looking Statements
Certain statements in this press release are
"forward-looking statements." These statements relate to future
events or the Company's future financial performance and involve
known and unknown risks, uncertainties and other factors that may
cause the actual results, levels of activity, performance or
achievements of the Company or its industry to be materially
different from those expressed or implied by any forward-looking
statements. In some cases, forward-looking statements can be
identified by terminology such as "may," "will," "could," "would,"
"should," "expect," "plan," "anticipate," "intend," "believe,"
"estimate," "predict," "potential" or the negative of those terms
or other comparable terminology. The Company has based these
forward-looking statements on its current expectations,
assumptions, estimates and projections. While the Company believes
these expectations, assumptions, estimates and projections are
reasonable, such forward-looking statements are only predictions
and involve known and unknown risks and uncertainties, many of
which are beyond the Company's control, including: the timing,
amount and cost of any share repurchases; future impairment
charges; customer acceptance of new products; competition from
other industry participants, some of whom have greater marketing
resources or larger market shares in certain product categories
than we do; pricing pressures from customers and consumers;
potential third-party claims and litigation, including litigation
relating to our restatement of previously-filed financial
information; potential impacts of ongoing or future government
investigations and regulatory initiatives; general economic
conditions; fluctuations in currency exchange rates and interest
rates; the consummation of announced acquisitions or dispositions,
and our ability to realize the desired benefits thereof; our
ability to achieve our guidance; our ability to execute and achieve
the desired benefits of announced cost-reduction efforts and other
initiatives; and the timing and expense to complete the announced
tender offer for certain of our outstanding notes. In
addition, the Company may identify and be unable to remediate one
or more material weaknesses in its internal control over financial
reporting. Furthermore, the Company and/or its subsidiaries may
incur additional tax liabilities in respect of 2016 and prior years
as a result of any restatement or may be found to have breached
certain provisions of Irish company legislation in respect of prior
financial statements and if so may incur additional expenses and
penalties. These and other important factors, including those
discussed under "Risk Factors" in the Company's Form 10-K for the
year ended December 31,
2016, as well as the Company's subsequent filings with the
United States Securities and Exchange Commission, may cause actual
results, performance or achievements to differ materially from
those expressed or implied by these forward-looking statements. The
forward-looking statements in this press release are made only as
of the date hereof, and unless otherwise required by applicable
securities laws, the Company disclaims any intention or obligation
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/perrigo-announces-the-launch-of-generic-equivalents-to-derma-smoothefs-scalp-oil-and-body-oil-300477463.html
SOURCE Perrigo Company plc